on CROSSJECT (EPA:ALCJ)
Maxim Group Recommends CROSSJECT with €4.00 Target Price
Maxim Group, a US brokerage focused on biopharmaceuticals, has initiated coverage of CROSSJECT, a specialty pharma company. They have issued a BUY recommendation for CROSSJECT's shares, setting a target price of €4.00. As of May 29, 2025, the shares were priced at €1.77.
CROSSJECT, headquartered in Dijon, France, specializes in needle-free auto-injector platforms for emergency therapies. Their flagship product, ZEPIZURE®, is in advanced phases of development and registration. The company has a significant contract with BARDA for this epileptic rescue therapy.
Patrick Alexandre, CEO of CROSSJECT, expressed enthusiasm for Maxim's endorsement, emphasizing their commitment to advancing developments, especially in North America.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news